JP2018521033A - 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 - Google Patents
三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 Download PDFInfo
- Publication number
- JP2018521033A JP2018521033A JP2017564557A JP2017564557A JP2018521033A JP 2018521033 A JP2018521033 A JP 2018521033A JP 2017564557 A JP2017564557 A JP 2017564557A JP 2017564557 A JP2017564557 A JP 2017564557A JP 2018521033 A JP2018521033 A JP 2018521033A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperazin
- hexahydrobenzo
- oxo
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- RLOVQSDUNXYXEW-UHFFFAOYSA-N CC(C1=C(c2ccc(CCl)cc2N)NCCC1)=O Chemical compound CC(C1=C(c2ccc(CCl)cc2N)NCCC1)=O RLOVQSDUNXYXEW-UHFFFAOYSA-N 0.000 description 1
- ZMCBYSBVJIMENC-UHFFFAOYSA-N CCOC(c1cc(N)ccc1)=O Chemical compound CCOC(c1cc(N)ccc1)=O ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
- AMCACAXNHBPZEO-UHFFFAOYSA-N CCOC(c1cccc(NC(c2cccnc2Cl)=O)c1)=O Chemical compound CCOC(c1cccc(NC(c2cccnc2Cl)=O)c1)=O AMCACAXNHBPZEO-UHFFFAOYSA-N 0.000 description 1
- IBQMAPSJLHRQPE-UHFFFAOYSA-N FC(c(cc1)ccc1N1CCNCC1)(F)F Chemical compound FC(c(cc1)ccc1N1CCNCC1)(F)F IBQMAPSJLHRQPE-UHFFFAOYSA-N 0.000 description 1
- NAZKLLYRVKKHAN-UHFFFAOYSA-N O=C1Nc2cc(CCl)ccc2C2=C1CCCN2 Chemical compound O=C1Nc2cc(CCl)ccc2C2=C1CCCN2 NAZKLLYRVKKHAN-UHFFFAOYSA-N 0.000 description 1
- IBRSSZOHCGUTHI-UHFFFAOYSA-N OC(c1cccnc1Cl)=O Chemical compound OC(c1cccnc1Cl)=O IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 1
- GVXPOEVDJWMNTQ-UHFFFAOYSA-N OCc(cc1)cc(N2)c1C(NCCC1)=C1C2=O Chemical compound OCc(cc1)cc(N2)c1C(NCCC1)=C1C2=O GVXPOEVDJWMNTQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0081021 | 2015-06-09 | ||
| KR20150081021 | 2015-06-09 | ||
| PCT/KR2016/005911 WO2016200101A2 (ko) | 2015-06-09 | 2016-06-03 | 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019088851A Division JP6806969B2 (ja) | 2015-06-09 | 2019-05-09 | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2018521033A true JP2018521033A (ja) | 2018-08-02 |
Family
ID=57503424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564557A Ceased JP2018521033A (ja) | 2015-06-09 | 2016-06-03 | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
| JP2019088851A Active JP6806969B2 (ja) | 2015-06-09 | 2019-05-09 | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019088851A Active JP6806969B2 (ja) | 2015-06-09 | 2019-05-09 | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10464919B2 (https=) |
| EP (1) | EP3312177B1 (https=) |
| JP (2) | JP2018521033A (https=) |
| KR (1) | KR101837047B1 (https=) |
| CN (1) | CN107849040B (https=) |
| AU (1) | AU2016276806B9 (https=) |
| BR (1) | BR112017026392B1 (https=) |
| CA (1) | CA2990277C (https=) |
| CL (1) | CL2017003138A1 (https=) |
| DK (1) | DK3312177T3 (https=) |
| ES (1) | ES2870203T3 (https=) |
| MX (1) | MX375707B (https=) |
| MY (1) | MY194590A (https=) |
| NZ (1) | NZ738187A (https=) |
| PH (1) | PH12017502228B1 (https=) |
| PL (1) | PL3312177T3 (https=) |
| PT (1) | PT3312177T (https=) |
| RU (1) | RU2715413C2 (https=) |
| SA (1) | SA517390509B1 (https=) |
| WO (1) | WO2016200101A2 (https=) |
| ZA (1) | ZA201708663B (https=) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019163287A (ja) * | 2015-06-09 | 2019-09-26 | ジェイル ファーマシューティカル カンパニー リミテッド | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
| JP2022541483A (ja) * | 2019-07-19 | 2022-09-26 | アストラゼネカ・アクチエボラーグ | Ｐａｒｐ１阻害薬 |
| JP2023532257A (ja) * | 2020-06-25 | 2023-07-27 | アストラゼネカ・アクチエボラーグ | 抗がん薬としてのキノキサリン誘導体 |
| JP2023538434A (ja) * | 2020-08-19 | 2023-09-07 | ユニヴァーシティ・オブ・オックスフォード | Ｌｍｏ２タンパク質阻害剤 |
| JP2024514703A (ja) * | 2021-04-22 | 2024-04-02 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 |
| JP2024518509A (ja) * | 2021-05-18 | 2024-05-01 | オンコニック セラピューティクス インコーポレイテッド | Ｐａｒｐ阻害剤抵抗性癌治療剤 |
| JP2024519334A (ja) * | 2021-05-18 | 2024-05-10 | オンコニック セラピューティクス インコーポレイテッド | 三環式誘導体化合物の結晶形及びその製造方法並びにそれを含む薬学的組成物 |
| JP2025516367A (ja) * | 2022-05-07 | 2025-05-27 | メッドシャイン ディスカバリー インコーポレイテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180252A1 (es) | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| KR101775356B1 (ko) | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| CN109689654A (zh) | 2016-07-11 | 2019-04-26 | 拜耳医药股份有限公司 | 7-取代的1-吡啶基-萘啶-3-甲酰胺类及其用途 |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| CN108727377A (zh) * | 2017-04-14 | 2018-11-02 | 四川大学 | 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途 |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| US20220110936A1 (en) * | 2019-02-02 | 2022-04-14 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof |
| EP3953360B1 (en) * | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| MX2022001200A (es) * | 2019-07-29 | 2022-02-21 | Jeil Pharmaceutical Co Ltd | Metodo para el tratamiento de accidente cerebrovascular usando un derivado triciclico. |
| US20220324899A1 (en) * | 2019-08-14 | 2022-10-13 | Metro International Biotech, Llc | Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| AU2020372682A1 (en) * | 2019-10-31 | 2022-06-09 | Jd Bioscience Inc. | Tricyclic compound and pharmaceutical use thereof |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| CA3190277A1 (en) | 2020-09-03 | 2022-03-10 | Joerg Benz | Heterocyclic compounds |
| US11591331B2 (en) | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| EP4342470A4 (en) * | 2021-05-18 | 2025-04-30 | Onconic Therapeutics Inc. | THERAPEUTIC AGENT FOR PARP INHIBITOR-RESISTANT CANCER |
| WO2023011608A1 (zh) * | 2021-08-05 | 2023-02-09 | 上海枢境生物科技有限公司 | 含三并环类衍生物调节剂、其制备方法和应用 |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| US20250163022A1 (en) * | 2021-12-22 | 2025-05-22 | Synnovation Therapeutics, Inc. | Parp1 inhibitors |
| KR20240134366A (ko) * | 2022-01-13 | 2024-09-09 | 에이스랜드 테라퓨틱스 (홍콩) 리미티드 | 피페라진 고리 함유 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CN119013279A (zh) * | 2022-03-11 | 2024-11-22 | 上海瑛派药业有限公司 | 作为parp抑制剂的取代的三环类化合物及其应用 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024099416A1 (zh) * | 2022-11-10 | 2024-05-16 | 上海海和药物研究开发股份有限公司 | 一种稠合三环类parp1抑制剂、其制备方法及用途 |
| WO2024255697A1 (zh) * | 2023-06-13 | 2024-12-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521698A (ja) * | 2002-03-26 | 2005-07-21 | 藤沢薬品工業株式会社 | 新規な三環式化合物 |
| WO2009061131A2 (en) * | 2007-11-06 | 2009-05-14 | Je Il Pharmaceutical Co., Ltd. | Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
| JP2011500758A (ja) * | 2007-10-26 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキノリノン誘導体 |
| JP2012508273A (ja) * | 2008-11-11 | 2012-04-05 | ジェ イル ファーマシューティカル カンパニー リミテッド | 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物 |
| EP3321377A1 (en) * | 2015-07-06 | 2018-05-16 | The Asan Foundation | Method for determining sensitivity to simultaneous inhibitor against parp and tankyrase |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391554A (en) * | 1992-09-09 | 1995-02-21 | Warner-Lambert Company | Dihydro- and tetrahydronaphthyridines |
| DE102004028973A1 (de) | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| BRPI0719123A2 (pt) * | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| KR101827444B1 (ko) | 2012-02-01 | 2018-02-08 | 제일약품주식회사 | 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 |
| MX375707B (es) * | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
-
2016
- 2016-06-03 MX MX2017016013A patent/MX375707B/es active IP Right Grant
- 2016-06-03 PH PH1/2017/502228A patent/PH12017502228B1/en unknown
- 2016-06-03 BR BR112017026392-0A patent/BR112017026392B1/pt active IP Right Grant
- 2016-06-03 KR KR1020160069199A patent/KR101837047B1/ko active Active
- 2016-06-03 WO PCT/KR2016/005911 patent/WO2016200101A2/ko not_active Ceased
- 2016-06-03 AU AU2016276806A patent/AU2016276806B9/en active Active
- 2016-06-03 JP JP2017564557A patent/JP2018521033A/ja not_active Ceased
- 2016-06-03 NZ NZ738187A patent/NZ738187A/en unknown
- 2016-06-03 MY MYPI2017704653A patent/MY194590A/en unknown
- 2016-06-03 CA CA2990277A patent/CA2990277C/en active Active
- 2016-06-03 ES ES16807741T patent/ES2870203T3/es active Active
- 2016-06-03 US US15/579,692 patent/US10464919B2/en active Active
- 2016-06-03 DK DK16807741.0T patent/DK3312177T3/da active
- 2016-06-03 RU RU2017146130A patent/RU2715413C2/ru active
- 2016-06-03 PT PT168077410T patent/PT3312177T/pt unknown
- 2016-06-03 PL PL16807741T patent/PL3312177T3/pl unknown
- 2016-06-03 CN CN201680040992.8A patent/CN107849040B/zh active Active
- 2016-06-03 EP EP16807741.0A patent/EP3312177B1/en active Active
-
2017
- 2017-12-07 SA SA517390509A patent/SA517390509B1/ar unknown
- 2017-12-07 CL CL2017003138A patent/CL2017003138A1/es unknown
- 2017-12-19 ZA ZA2017/08663A patent/ZA201708663B/en unknown
-
2019
- 2019-05-09 JP JP2019088851A patent/JP6806969B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521698A (ja) * | 2002-03-26 | 2005-07-21 | 藤沢薬品工業株式会社 | 新規な三環式化合物 |
| JP2011500758A (ja) * | 2007-10-26 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキノリノン誘導体 |
| WO2009061131A2 (en) * | 2007-11-06 | 2009-05-14 | Je Il Pharmaceutical Co., Ltd. | Novel tricyclic derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
| JP2012508273A (ja) * | 2008-11-11 | 2012-04-05 | ジェ イル ファーマシューティカル カンパニー リミテッド | 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物 |
| EP3321377A1 (en) * | 2015-07-06 | 2018-05-16 | The Asan Foundation | Method for determining sensitivity to simultaneous inhibitor against parp and tankyrase |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019163287A (ja) * | 2015-06-09 | 2019-09-26 | ジェイル ファーマシューティカル カンパニー リミテッド | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 |
| JP7641944B2 (ja) | 2019-07-19 | 2025-03-07 | アストラゼネカ・アクチエボラーグ | Ｐａｒｐ１阻害薬 |
| JP2022541483A (ja) * | 2019-07-19 | 2022-09-26 | アストラゼネカ・アクチエボラーグ | Ｐａｒｐ１阻害薬 |
| US12606555B2 (en) | 2019-07-19 | 2026-04-21 | Astrazeneca Ab | Chemical compounds |
| JP2023532257A (ja) * | 2020-06-25 | 2023-07-27 | アストラゼネカ・アクチエボラーグ | 抗がん薬としてのキノキサリン誘導体 |
| JP7769650B2 (ja) | 2020-06-25 | 2025-11-13 | アストラゼネカ・アクチエボラーグ | 抗がん薬としてのキノキサリン誘導体 |
| JP2023538434A (ja) * | 2020-08-19 | 2023-09-07 | ユニヴァーシティ・オブ・オックスフォード | Ｌｍｏ２タンパク質阻害剤 |
| JP7850458B2 (ja) | 2020-08-19 | 2026-04-23 | ユニヴァーシティ・オブ・オックスフォード | Ｌｍｏ２タンパク質阻害剤 |
| JP2024514703A (ja) * | 2021-04-22 | 2024-04-02 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用 |
| JP2024519334A (ja) * | 2021-05-18 | 2024-05-10 | オンコニック セラピューティクス インコーポレイテッド | 三環式誘導体化合物の結晶形及びその製造方法並びにそれを含む薬学的組成物 |
| JP2024518509A (ja) * | 2021-05-18 | 2024-05-01 | オンコニック セラピューティクス インコーポレイテッド | Ｐａｒｐ阻害剤抵抗性癌治療剤 |
| JP7809725B2 (ja) | 2021-05-18 | 2026-02-02 | オンコニック セラピューティクス インコーポレイテッド | 三環式誘導体化合物の結晶形及びその製造方法並びにそれを含む薬学的組成物 |
| JP2025516367A (ja) * | 2022-05-07 | 2025-05-27 | メッドシャイン ディスカバリー インコーポレイテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
| JP7835895B2 (ja) | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6806969B2 (ja) | 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物 | |
| CN116568681B (zh) | Sos1抑制剂、包含其的药物组合物及其用途 | |
| JP4287649B2 (ja) | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 | |
| KR100441362B1 (ko) | 혈관 형성 억제 활성을 갖는 프탈라진 | |
| JP2004517860A (ja) | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 | |
| JP7323637B2 (ja) | 置換複素環式アミド化合物、その調製方法、及びその医薬的使用 | |
| KR20200094168A (ko) | 할로-알릴아민 ssao/vap-1 억제제 및 그의 용도 | |
| KR20120089459A (ko) | 키나제 저해제로서 5,6-바이사이클릭 헤테로아릴-함유 우레아 화합물 | |
| JPWO2016208592A1 (ja) | 二環性複素環アミド誘導体 | |
| JP7561285B2 (ja) | 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用 | |
| CA2983040C (en) | Heterocyclic-imidazole compounds, pharmaceutical compositions thereof, preparation method therefor and use thereof | |
| US9567333B2 (en) | Triazolopyridyl compounds as aldosterone synthase inhibitors | |
| AU2016214492A1 (en) | 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity | |
| US20130231354A1 (en) | Substituted azaindazole compounds | |
| JP6140168B2 (ja) | アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体 | |
| CN119866333A (zh) | Kit抑制剂、化合物、药物组合物及其使用方法 | |
| TWI917498B (zh) | Ｓｏｓ１抑制劑、包含其的藥物組合物及其用途 | |
| WO2024105364A1 (en) | Heterocyclic inhibitors of cdc-like kinases | |
| CN120647661A (zh) | 三并杂环类化合物及其用途 | |
| JP2022549678A (ja) | 複素環誘導体及びその使用 | |
| HK1185079A1 (zh) | 新型二环式化合物或其盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171221 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190311 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190409 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20190827 |